CymaBay Therapeutics (NASDAQ:CBAY) will announce its earnings results after the market closes on Wednesday, May 8th. Analysts expect the company to announce earnings of ($0.34) per share for the quarter.
CymaBay Therapeutics (NASDAQ:CBAY) last announced its quarterly earnings results on Thursday, February 28th. The biopharmaceutical company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.04. On average, analysts expect CymaBay Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Shares of CBAY stock opened at $13.08 on Tuesday. CymaBay Therapeutics has a 52 week low of $6.31 and a 52 week high of $15.00. The firm has a market capitalization of $901.27 million, a P/E ratio of -10.38 and a beta of 1.77.
A number of analysts recently commented on CBAY shares. Piper Jaffray Companies set a $30.00 price target on CymaBay Therapeutics and gave the stock a “buy” rating in a research note on Friday, March 1st. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $20.00 price target on shares of CymaBay Therapeutics in a research note on Friday, February 1st. Roth Capital reaffirmed a “buy” rating on shares of CymaBay Therapeutics in a research note on Tuesday, February 19th. Oppenheimer set a $18.00 price target on CymaBay Therapeutics and gave the stock a “buy” rating in a research note on Friday, February 15th. Finally, BidaskClub raised CymaBay Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, February 27th. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and an average price target of $19.38.
In other CymaBay Therapeutics news, Director Carl Goldfischer sold 11,675 shares of the firm’s stock in a transaction on Thursday, February 7th. The stock was sold at an average price of $9.02, for a total transaction of $105,308.50. Following the completion of the transaction, the director now owns 2,335 shares of the company’s stock, valued at $21,061.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 4.50% of the company’s stock.
About CymaBay Therapeutics
CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.
See Also: Put Option Volume
Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.